VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma

Abstract

Papillary thyroid carcinoma (PTC) is the most common type of endocrine cancer, with an increasing incidence worldwide. The treatment of PTC is currently the subject of clinical controversy, making it critically important to identify molecular markers that would help improve the risk stratification of PTC patients and optimize the therapeutic approach. The VHL tumor suppressor gene has been implicated in tumorigenesis of various types of carcinoma and linked with their aggressive biological behavior. The role of VHL in the origin and development of PTC has only recently begun to be revealed. In this narrative review we attempt to summarize the existing knowledge that implicates VHL in PTC pathogenesis and to outline its potential significance as a candidate molecular biomarker for the grouping of PTC patients into high and low risk groups.

Differential microRNA expression for diagnosis and prognosis of papillary thyroid cancer

“…The investigation revealed that a group of miR-25-3p, miR-296-5p, and miR-92a-3p were overexpressed in PTC patient samples compared to controls. Moreover, miR-25-3p, miR-296-5p, and miR-92a-3p target the genes AKT1, PLK1, and VHL1, respectively (Table 1) (29,41,46). Furthermore, the diagnostic value was assessed by the areas under the curves (AUC), and the values were statistically significant, with values of 0.727, 0.771, and 0.862, respectively.…”

“…The VHL is a tumor suppressor gene that is downregulated in some types of cancer. This gene dysregulation is involved in the development of carcinomas and clinically manifests aggressive behavior ( 29 ).…”